Compare VRCA & MNTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRCA | MNTS |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.0M | 74.2M |
| IPO Year | 2018 | 2019 |
| Metric | VRCA | MNTS |
|---|---|---|
| Price | $3.79 | $2.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $13.83 | N/A |
| AVG Volume (30 Days) | 45.3K | ★ 585.2K |
| Earning Date | 11-13-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $35,577,000.00 | $1,110,000.00 |
| Revenue This Year | N/A | $660.36 |
| Revenue Next Year | $58.01 | $42.18 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 370.22 | N/A |
| 52 Week Low | $3.28 | $0.44 |
| 52 Week High | $9.82 | $22.20 |
| Indicator | VRCA | MNTS |
|---|---|---|
| Relative Strength Index (RSI) | 35.23 | 26.17 |
| Support Level | N/A | N/A |
| Resistance Level | $5.94 | $4.44 |
| Average True Range (ATR) | 0.35 | 0.23 |
| MACD | -0.05 | -0.09 |
| Stochastic Oscillator | 19.48 | 19.40 |
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
Momentus Inc is a U.S.-based commercial space company engaged in providing satellites, satellite buses, and in-space infrastructure services. The company offers space transportation, hosted payload, and in-orbit servicing solutions, including last-mile satellite delivery, refueling, inspection, maintenance, and debris removal. It also develops satellite technologies such as solar arrays and propulsion systems, and provides production and operation of small satellites for government, defense, and commercial customers.